Navigation Links
Favrille Reports First Quarter 2008 Financial Results
Date:5/8/2008

irst quarter of 2007.

Marketing, general and administrative expense was approximately $2.6 million for the first quarter of 2008, compared to approximately $2.9 million during the same period in 2007. The decrease is primarily due to a decrease in cash bonus expense, stock-based compensation and travel expenses. Total stock-based compensation included in marketing, general and administrative expense was approximately $560,000 for the quarter, compared to approximately $660,000 for the first quarter of 2007.

As of March 31, 2008, Favrille had cash, cash equivalents and short-term investments of $19.7 million, compared to $29.9 million at December 31, 2007. The decrease is primarily due to net cash used to fund ongoing operations. Loan and security agreements with Favrille's senior lenders require the Company to maintain a minimum of $15 million in available cash, cash equivalents and short-term investments. In the event Favrille's available cash should fall below the minimum requirement, the lenders could require a letter of credit equal to the outstanding loan balances at that time, in which case the Company would be required to use a significant amount of its available cash for collateral.

"For the past eight years we have worked diligently to fund the company, from inception up to and including our Phase 3 registration trial, while making every effort to maximize shareholder value," said Tamara A. Seymour, Chief Financial Officer of Favrille. "We expect that our cash on hand is sufficient to fund operations through our Phase 3 data analysis this quarter, after which we will explore our financing options."

Phase 3 Registration Trial Update

Favrille reached the data cutoff date for its Phase 3 registration trial of Specifid following Rituxan(R) in patients with follicular B-cell non-Hodgkin's lymphoma (NHL) in April 2008. As of the data cutoff date, 205 of the 349 patients randomized have experienced disease progression (relapsed)
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
2. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
3. Favrille Announces $21.1 Million Registered Direct Offering
4. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIO InvestorForum
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Favrille CEO to Present at Bear Stearns Healthcare Conference
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
(Date:8/21/2014)...  China Cord Blood Corporation (NYSE: CO ... financial results for the first quarter of fiscal year ... in the US.  The Company will ... Friday, August 29, 2014 to discuss its financial performance ... developments, followed by a question and answer session.  Interested ...
(Date:8/21/2014)... Aug. 21, 2014  Four-dimensional (4-D) printing develops ... on external stimuli such as changes in temperature. ... disruptive effect in multiple industries.  In the near ... by printing objects ranging from human organs to ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... Pursuit Solutions ( http://www.pursuit-solutions.com ), ... services for Life Sciences sales and marketing organizations, ... New Commercial Sales Models” by Peter Robinson, co-founder ... article examines some innovative models used to improve ... in the pharmaceutical market. Robinson grades the industry ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... 5 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:,SDI) today ... Toray,Medical Co. Ltd. for the marketing and sale ... cleared assay for the measurement of,endotoxin. Under the ... access to Toray,s distributors in new geographic territories,including ...
... with Bioscene in Japan - Expands Presence in Japan, ... announced,today that the Japan Patent Office (JPO) has licensed ... Inc. (Bioscene) as,its exclusive partner for the distribution of ... assist the JPO in the review and approval,of patent ...
... YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ... commercializes differentiated products for patients worldwide,today announced that ... AeroLEF(TM) will be presented at The 27th Annual,Scientific ... place May,8-10, 2008 in Tampa, Florida., The ...
Cached Biology Technology:Spectral and Toray expand collaboration to include new geographic territories 2Spectral and Toray expand collaboration to include new geographic territories 3Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 2Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 3Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 4YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING 2
(Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor ... was named a fellow in the International Society for the ... is one of four members two from the U.S., ... fellows in 2014. Fellows are elected every three years, and ... members from more than 20 countries, the ISSOL includes researchers ...
(Date:8/20/2014)... ITHACA, N.Y. In a study of 158 pregnant ... the craving and intentional consumption of ice, cornstarch, ... items, reports a new Cornell study. , Moreover, such ... teens who did not eat nonfood substances. , Pregnant ... low hemoglobin, which can lead to iron deficiency and ...
(Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... fever is a terrible viral disease blighting many of the ... aegypti , 40% of the world,s population is believed to ... exposure to other strains of the fever does not confer ... result in fatal dengue haemorrhagic fever. The lack of a ...
... become more educated, studies have demonstrated that they tend to ... nutrients. They also pay more. In a study published in ... American Dietetic Association , researchers from the University of Washington ... of 164 adults in the Seattle, Washington area. The ...
... BIO-key International, Inc. (OTC Bulletin Board: BKYI) today ... on Wednesday, May 6, 2009 before the market opens. ... a conference call, which will be broadcast live over ... a.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ), ...
Cached Biology News:Mosquito parasite may help fight dengue fever 2People of higher socioeconomic status choose better diets -- but pay more per calorie 2BIO-key(R) Announces First Quarter Earnings Release and Conference Call Schedule 2
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
... with Purpose -- The Varian ... the highest level of flexibility ... an affordable, easy-to-use system. The ... workstation guarantees success with today's ...
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Biology Products: